| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... New England Journal of Medicine 369 (6), 507-516, 2013 | 1930 | 2013 |
| Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study B Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ... Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 1998 | 1309 | 1998 |
| Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ... Annals of oncology 26, v116-v125, 2015 | 1135 | 2015 |
| Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma P Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ... New England Journal of Medicine 374 (25), 2419-2429, 2016 | 871 | 2016 |
| Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts MS Cragg, SM Morgan, HTC Chan, BP Morgan, AV Filatov, ... Blood, The Journal of the American Society of Hematology 101 (3), 1045-1052, 2003 | 839 | 2003 |
| Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ... New England Journal of Medicine 372 (17), 1598-1607, 2015 | 821 | 2015 |
| Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of … D Cunningham, EA Hawkes, A Jack, W Qian, P Smith, P Mouncey, ... The Lancet 381 (9880), 1817-1826, 2013 | 670 | 2013 |
| Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study AK Clift, CAC Coupland, RH Keogh, K Diaz-Ordaz, E Williamson, ... bmj 371, 2020 | 613 | 2020 |
| European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma … JM Foran, AZS Rohatiner, D Cunningham, RA Popescu, P Solal-Celigny, ... Journal of Clinical Oncology 18 (2), 317-317, 2000 | 602 | 2000 |
| Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ... Journal of Clinical Oncology 37 (15), 1285-1295, 2019 | 581 | 2019 |
| Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the … AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... The Lancet Haematology 3 (5), e217-e227, 2016 | 570 | 2016 |
| Clinical trials of antibody therapy MJ Glennie, PWM Johnson Immunology today 21 (8), 403-410, 2000 | 501 | 2000 |
| Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... Blood, The Journal of the American Society of Hematology 126 (6), 739-745, 2015 | 482 | 2015 |
| Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. PW Johnson, AZ Rohatiner, JS Whelan, CG Price, S Love, J Lim, ... Journal of clinical oncology 13 (1), 140-147, 1995 | 413 | 1995 |
| Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection SA Beers, RR French, HTC Chan, SH Lim, TC Jarrett, RM Vidal, ... Blood, The Journal of the American Society of Hematology 115 (25), 5191-5201, 2010 | 410 | 2010 |
| Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma SF Barrington, W Qian, EJ Somer, A Franceschetto, B Bagni, E Brun, ... European journal of nuclear medicine and molecular imaging 37, 1824-1833, 2010 | 391 | 2010 |
| Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study J Hippisley-Cox, CAC Coupland, N Mehta, RH Keogh, K Diaz-Ordaz, ... bmj 374, 2021 | 370 | 2021 |
| Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study SM Ansell, MC Minnema, P Johnson, JM Timmerman, P Armand, ... Journal of Clinical Oncology 37 (6), 481-489, 2019 | 360 | 2019 |
| The mechanisms of action of rituximab in the elimination of tumor cells P Johnson, M Glennie Seminars in oncology 30 (1), 3-8, 2003 | 359 | 2003 |
| First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial A Hagenbeek, O Gadeberg, P Johnson, L Møller Pedersen, J Walewski, ... Blood, The Journal of the American Society of Hematology 111 (12), 5486-5495, 2008 | 349 | 2008 |
